A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies

Ulcerative Colitis Clinical Trial

— ImmUniverse  

Official title:

A Multicentre Prospective Longitudinal Observational Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05456893
• Other study ID #: 021-A01092-39
• Status: Recruiting
• Start date: July 28, 2022
• Est. completion date: September 9, 2027

Study information

• Verified date: June 2023
• Source: Central Hospital, Nancy, France
• Contact: Laurent MD Peyrin-Biroulet, PhD
• Phone: 0383153661
• Email: peyrinbiroulet[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

UC is a chronic, idiopathic form of intestinal inflammatory disease (IBD) that affects the colon, most commonly afflicting adults aged 30-40 years and resulting in disability and lower quality of life (1). It is characterized by relapsing and remitting mucosal inflammation, starting in the rectum and extending to proximal segments of the colon. Although biologic therapies have provided clinical benefits to patients, these goals are still poorly met, due to the limited knowledge of the underlying mechanisms of immunopathology and the lack of predictive biomarkers that would allow proper patient stratification.

The hypothesis of this study is that by identifying new biomarkers in blood, stool and tissue that (i) predict response (or non-response) to therapy prior to the start of treatment and (ii) predict response to therapy in the early phase of treatment will allow to find the right treatment for the right patient (personalized medicine).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 95
• Est. completion date: September 9, 2027
• Est. primary completion date: December 9, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female patients = 18 years of age (at the time of signing the ICF)

• Established diagnosis of ulcerative colitis with a minimum disease duration of 3 months

• Moderate to severe active UC defined by Mayo Score = 6

• Moderate to severe active UC defined by endoscopy score of =2

• Indication to start any biological or small molecule agent (anti-TNF, anti- IL12/23, anti-integrin and JAK-inhibitors)

• In case of treatment with corticosteroid: stable dose for at least 3 weeks prior to baseline, dosage = 20 mg prednisone

• Indication for an endoscopy for the assessment of disease activity as for standards of care and current guidelines

• Able to comply with the study procedures

• Person affiliated to or beneficiary of a social security plan

• Person informed about study organization and able to sign informed consent form

Exclusion Criteria:

• Diagnosis of indeterminate colitis, microscopic colitis, ischaemic colitis, infectious colitis, radiation colitis

• Absolute contraindications to endoscopy procedures or complication during previous endoscopy

• Bleeding disorders

• Indication for surgery for UC

• Rectal topical therapy (enemas or suppositories) = 2 weeks prior to baseline

• Treatment with > 20 mg prednisone within 3 weeks prior to baseline

• Anaemia (haemoglobin < 10 g/dl) at baseline

• Any circumstances which could contradict a study participation and lead the Investigator to assess the patient as unsuitable for study participation for any other reason

• Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the Public Health Code:

• Pregnant, parturient or breastfeeding woman

• Minor person (non-emancipated)

• Adult person under legal protection (any form of public guardianship)

• Adult person incapable of giving consent and not under legal protection

• Person deprived of liberty for judicial or administrative decision, person under psychiatric care as referred in articles L. 3212-1 and L. 3213-1

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Inflammatory Bowel Diseases
• Ulcer
• Ulcerative Colitis

Intervention

Procedure:
• Procedure: endoscopic biopsy
Per-endoscopic biopsies
• Blood sampling
Blood sampling
• stool sampling
stool sampling

Locations

Country	Name	City	State
France	Central Hospital	Nancy	Lorraine

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of subjects who achieve clinical response at week 14.	Clinical response will be defined as overall Mayo score of 2 or smaller with Mayo endoscopy score (Mayo ES) of 0 or 1 (without friability), and bleeding subscore of 0.; The Clinical Response will be categorized in four subcategories: Super responder: meets criteria of clinical response; Responder: Mayo Score: reduction of 50%/ improvement of = 3 from baseline, but does not meet criteria of remission; endoscopic Mayo: does not meet criteria of clinical response, but shows reduction of Mayo ES; Partial responder: Mayo Score: reduction of up to 30%, endoscopic Mayo: no formal improvement by Mayo ES but in overall assessment by the physician slight improvement.; Non-responder: reduction of less than 30% and in endoscopy no improvement in the overall assessment	The percentage of subjects who achieve clinical response at week 14
Primary	The percentage of subjects who achieve deep clinical remission at week 14.	Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) =1 and rectal bleeding (RB) = 0.	The percentage of subjects who achieve deep clinical remission at week 14
Primary	The percentage of subjects who achieve deep clinical remission at week 26.	Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) =1 and rectal bleeding (RB) = 0.	The percentage of subjects who achieve deep clinical remission at week 26.
Primary	The percentage of subjects who achieve deep clinical remission at week 52.	Deep clinical remission will be defined as partial Mayo Score 0-1 with stool frequency (SF) =1 and rectal bleeding (RB) = 0.	The percentage of subjects who achieve deep clinical remission at week 52.
Primary	The percentage of subjects who achieve mucosal healing at week 14.	Mucosal healing will be defined as Mayo endoscopic score = 0; Nancy histology index: ulceration: 0, neutrophils: 0, chronic infiltrate: 0 or 1.	The percentage of subjects who achieve mucosal healing at week 14.
Primary	The percentage of subjects who achieve mucosal healing at week 52.	Mucosal healing will be defined as Mayo endoscopic score = 0; Nancy histology index: ulceration: 0, neutrophils: 0, chronic infiltrate: 0 or 1.	The percentage of subjects who achieve mucosal healing at week 52.
Primary	The percentage of subjects who achieve symptomatic remission at week 14.	Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).	The percentage of subjects who achieve symptomatic remission at week 14.
Primary	The percentage of subjects who achieve symptomatic remission at week 26.	Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).	The percentage of subjects who achieve symptomatic remission at week 26.
Primary	The percentage of subjects who achieve symptomatic remission at week 52.	Symptomatic remission will be defined as reported by patient on PRO 2 (SF= 0-1 and RB= 0).	The percentage of subjects who achieve symptomatic remission at week 52.
Secondary	The percentage of subjects without any disease progression (e.g. flares) at week 14.	The percentage of subjects without any disease progression (e.g. flares) at week 14.	The percentage of subjects without any disease progression (e.g. flares) at week 14.
Secondary	The percentage of subjects without any disease progression (e.g. flares) at week 26.	The percentage of subjects without any disease progression (e.g. flares) at week 26.	The percentage of subjects without any disease progression (e.g. flares) at week 26.
Secondary	The percentage of subjects without any disease progression (e.g. flares) at week 52.	The percentage of subjects without any disease progression (e.g. flares) at week 52.	The percentage of subjects without any disease progression (e.g. flares) at week 52.
Secondary	The percentage of subjects who show an improvement on patient reported outcomes at week 14.	Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).	The percentage of subjects who show an improvement on patient reported outcomes at week 14.
Secondary	The percentage of subjects who show an improvement on patient reported outcomes at week 26.	Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).	The percentage of subjects who show an improvement on patient reported outcomes at week 26.
Secondary	The percentage of subjects who show an improvement on patient reported outcomes at week 52.	Patient reported outcomes include: PRO 2 (stool frequency (SF) and rectal bleeding (RB)), FACIT-F (level of fatigue), PROMIS Depression (level of depression), SF-36 (level of quality of life), Euro-QoL-5D (level of quality of life).	The percentage of subjects who show an improvement on patient reported outcomes at week 52.
Secondary	The percentage of subjects without the following complications until week 52 :	The percentage of subjects without the following complications until week 52: hospitalizations due to UC; treatment intensification including introduction of toxic long-term therapies (i.e. systemic glucocorticoids); new stenosis; new fistula; new development of primary sclerosing cholangitis (PSC); infections; intestinal surgery	week 52
Secondary	The percentage of subjects without long-term complications until week 104.	The percentage of subjects without long-term complications until week 104.	The percentage of subjects without long-term complications until week 104.